Description
|
Fudostein was launched in Japan as a new mucoactive agent for the treatment of bronchitis and respiratory congestion. This cysteine derivative was obtained from L-cysteine by condensation with either allylic alcohol in the presence of potassium persu lfate or the corresponding bromoalcohol in the presence of a base. Fudostein was shown to significantly reduce mucus glycoprotein hypersecretion and inhibit infiltration of airway mucosa by lymphocytes and inflammatory cells in bronchitic rats. When given to bronchitic rabbits, an oral dose of 500 mg/kg daily potently decreased the fucose/ N-acetylneuraminic acid in sputa, so exhibiting mucoregulatory properties. In another study with SO
2
-exposed rabbits, fudostein suppressed blood flow of tracheal microvasculature increased by SO
2
, partly due to scavenging of superoxide anion.
|
Chemical Properties
|
Off-White Powder
|
Originator
|
SS Pharmaceutical/Mitsubishi Pharma (Japan)
|
Uses
|
An antiinflammatory expectorant MUC5 mucin obstructive pulmonary disease.
|
Uses
|
Fudosteine is a novel mucoactive agent and a MUC5AC mucin hypersecretion inhibitor. MUC5AC mucin synthesis and the expression of the MUC5AC gene were increased by LPS in rats or TNF-α in NCI-H292 cells; these effects were inhibited by fudosteine treatment
|
Uses
|
An antiinflammatory expectorant used in the treatment of MUC5 mucin obstructive pulmonary disease.
|
Uses
|
A demonstrated antiinflammatory
|
Uses
|
Fudosteine is a cysteine derivative that interferes with the increase in goblet cell number, expression of the mucin MUC5AC, and subsequent mucin secretion, in airways agonized with tobacco smoke, isoproterenol, lipopolysaccharide, TNF-α, or oxidants. Fudosteine, which is a thiol compound with antioxidant properties, limits NF-κB signaling and reduces inflammatory gene expression. It has greater bioavailability than N-acetyl-cysteine and increases cysteine levels in cells.
|
Brand name
|
Cleanal
|
Hazard
|
A reproductive hazard.
|